Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEH1 | O60930 | 1/20 | 0.62 |
| ▸ | TYR | P14679 | 3/20 | 0.57 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | MDM4 | O15151 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23250698 | 0.83 | PTGS1 (0.59) | RNASEH1TYRTRPA1PTGS1CACNA1C | |
| SCHEMBL6214362 | 0.83 | PTGS1 (0.70) | RNASEH1TYRTRPA1PTGS1CACNA1C | |
| SCHEMBL23258806 | 0.82 | TRPA1 (0.52) | RNASEH1TYRTRPA1PTGS1CACNA1C | |
| SCHEMBL9158006 | 0.82 | TRPA1 (0.52) | RNASEH1TYRTRPA1PTGS1CACNA1C | |
| SCHEMBL23250678 | 0.82 | TRPA1 (0.52) | RNASEH1TYRTRPA1PTGS1CACNA1C | |
| SCHEMBL23258510 | 0.82 | RNASEH1 (0.56) | RNASEH1TYRTRPA1PTGS1CACNA1C | |
| SCHEMBL23258824 | 0.82 | RNASEH1 (0.56) | RNASEH1TYRTRPA1PTGS1CACNA1C | |
| SCHEMBL29362968 | 0.81 | TRPA1 (0.67) | RNASEH1TYRTRPA1PTGS1CACNA1C | |
| SCHEMBL172232 | 0.81 | TRPA1 (0.67) | RNASEH1TYRTRPA1PTGS1CACNA1C | |
| SCHEMBL7442050 | 0.80 | TRPA1 (0.50) | RNASEH1TYRTRPA1PTGS1CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220339136-A1 | LIPOSOMAL TROPONOID COMPOUND FORMULATIONS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-10-27 | — | — | US | disclosed |
| EP-4021413-A1 | LIPOSOMAL TROPONOID COMPOUND FORMULATIONS | United States Government as Represented by The Department of Veterans Affairs (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-113105395-B | 4-phenylsulfonyl-1-trihydroxy benzoyl piperazine-2-carboxamide derivative and preparation method and application thereof | 山东大学 | 2022-06-17 | — | — | CN | disclosed |
| US-20210393548-A1 | INHIBITORS OF BUNYAVIRIDAE AND USES THEREOF | SAINT LOUIS UNIVERSITY (US) | 2021-12-23 | — | — | US | disclosed |
| US-10980754-B2 | Anti-fungal compounds | SAINT LOUIS UNIVERSITY (US) | 2021-04-20 | — | — | US | disclosed |
| US-20190099385-A1 | ANTI-FUNGAL COMPOUNDS | SAINT LOUIS UNIVERSITY (US) | 2019-04-04 | — | — | US | disclosed |
| WO-2017184752-A1 | ANTI-FUNGAL COMPOUNDS | SAINT LOUIS UNIVERSITY (US) | 2017-10-26 | — | — | WO | disclosed |
| US-20130209386-A1 | NEW USES | EVOCUTIS PLC (GB) | 2013-08-15 | — | — | US | disclosed |
| EP-2598208-A2 | NEW USES | Evocutis plc (GB) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012172318-A1 | FORMULATIONS CONTAINING TROPOLONOIDS, COPPER SALT AND A SOLVENT SYSTEM | EVOCUTIS PLC (GB) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012013967-A2 | NEW USES | SYNTOPIX GROUP PLC (GB) | 2012-02-02 | — | — | WO | disclosed |
| US-20100152301-A1 | Treatment of Viral Infections | GOVERNMENT OF THE US, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152301-A1 | Treatment of Viral Infections | GOVERNMENT OF THE US, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-06-17 | — | — | US | disclosed |
| US-20090283473-A1 | PLANT MATERIALS EXTRACTION METHOD | XYLON BIOTECHNOLOGIES LTD. | 2009-11-19 | — | — | US | disclosed |
| US-20090283473-A1 | PLANT MATERIALS EXTRACTION METHOD | XYLON BIOTECHNOLOGIES LTD. | 2009-11-19 | — | — | US | disclosed |
| US-20070219141-A1 | Plant Materials Extraction Method | JONES DAVID | 2007-09-20 | — | — | US | disclosed |
| US-20070219141-A1 | Plant Materials Extraction Method | JONES DAVID | 2007-09-20 | — | — | US | disclosed |
| WO-2007065007-A9 | TREATMENT OF VIRAL INFECTIONS | US HEALTH (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007065007-A2 | TREATMENT OF VIRAL INFECTIONS | GOVERNMENT OF THE U.S.A., AS REPERSENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210393548-A1 | INHIBITORS OF BUNYAVIRIDAE AND USES THEREOF | HAVCR2, REN, CTSE | RNASEH1 20/4885TYR 664/4885TRPA1 3922/4885 |
| US-20070219141-A1 | Plant Materials Extraction Method | ALPP, PLK4, PGLS | RNASEH1 1168/4885TYR 213/4885TRPA1 3148/4885 |
| US-20190099385-A1 | ANTI-FUNGAL COMPOUNDS | ERG28, NANS, DPM1 | RNASEH1 3291/4885TYR 188/4885TRPA1 4519/4885 |
| US-10980754-B2 | Anti-fungal compounds | ERG28, NANS, DPM1 | RNASEH1 3291/4885TYR 188/4885TRPA1 4519/4885 |
| US-20220339136-A1 | LIPOSOMAL TROPONOID COMPOUND FORMULATIONS | SMPD3, SMPD1, SMPD2 | RNASEH1 2963/4885TYR 609/4885TRPA1 1097/4885 |
| US-20100152301-A1 | Treatment of Viral Infections | CD4, TYMP, DUT | RNASEH1 162/4885TYR 4471/4885TRPA1 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.